Steve Mortillo

Statistics

Publications

Citations

244

H-Index

Active since

2005

Affiliations

Bristol-Myers Squibb (United States)(Current)

Steve Mortillo is an author at Bristol-Myers Squibb (United States) specializing in vascular endothelial growth factor inhibitors, tyrosine kinase inhibitors, and vascular endothelial growth factor.

Publications per year

2005–2008

Publications

Discovery of Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215)

Zhen‐Wei Cai, Yongzheng Zhang, R. M. Borzilleri et al. · Journal of Medicinal Chemistry · 2008 · 141 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Design, Synthesis, and Evaluation of Orally Active 4-(2,4-Difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Inhibitors

R. M. Borzilleri, Xiaoping Zheng, Ligang Qian et al. · Journal of Medicinal Chemistry · 2005 · 63 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Discovery and Evaluation of N-Cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a Selective and Orally Efficacious Inhibitor of Vascular Endothelial Growth Factor Receptor-2

R. M. Borzilleri, Rajeev S. Bhide, Joel C. Barrish et al. · Journal of Medicinal Chemistry · 2006 · 40 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

1–3 of 3